Negative-feedback control
Evidence context. Preclinical evidence.
Presynaptic α2 adrenoceptors can inhibit further norepinephrine release. Genetic and pharmacological evidence indicates an important role for α2A, with contributions from α2C in some preparations and activity regimes.
A receptor label does not imply identical function everywhere that receptor is expressed. Tissue, circuit, endogenous activity, and experimental method all affect the interpretation.
Functional heterogeneity
Evidence context. Preclinical evidence.
Projection-specific work in mouse locus coeruleus neurons suggests that somatodendritic α2-autoreceptor function can vary across neuronal populations. Receptor responses also depend on ligand, pathway, assay configuration, and timescale.
Aeviant treats subtype preference as one part of selectivity, not as a complete account of the physiological state created by a drug.
Positive allosteric modulation and direct agonism
Evidence context. Established biology.
A direct agonist activates a receptor through its own pharmacology. A positive allosteric modulator is defined by its effect on the response to a specified orthosteric ligand, under specified experimental conditions. Allosteric modulation does not automatically imply state dependence or an absence of intrinsic activity.
The distinction must be established experimentally. Ligand dependence, intrinsic agonism, subtype selectivity, and signalling behaviour are separate measurements rather than conclusions supplied by the modality label.
The AVX-1 research question
Evidence context. Program objective.
Aeviant’s hypothesis is that potentiating the α2A response to endogenous norepinephrine may help restore an autoinhibitory brake without forcing the receptor on through direct agonism.
The program objective is to identify and characterize a small-molecule positive allosteric modulator with a Gi-biased, arrestin-sparing profile. Endogenous-ligand dependence, low intrinsic agonism, subtype selectivity, signalling bias, CNS activity, and preservation of tonic or phasic dynamics are objectives, not results.
Limitations
α2A is not the only α2 autoreceptor subtype. Several foundational studies use mouse genetics, peripheral sympathetic preparations, or ex vivo tissue and should not be generalized directly to human central pharmacology.
Relevance to the current program
Aeviant is investigating whether positive allosteric modulation of α2A can potentiate the receptor’s response to endogenous norepinephrine without reproducing the exposure-driven profile of direct agonism. This remains unvalidated.
References and supporting evidence
The following records provide the principal public evidence used in this review. Their classifications and limitations remain part of the interpretation.
The α2A-adrenergic autoreceptor participates in negative-feedback regulation
Genetic and pharmacological studies indicate that α2A is an important presynaptic regulator of norepinephrine transmission, while α2C can also contribute depending on tissue and activity pattern.
Classification. Preclinical evidence.
Relevance to Aeviant. This feedback biology provides part of the published rationale for the AVX-1 research question.
Limitations. Key studies use knockout mice and peripheral or ex vivo preparations. They do not establish that α2A is the sole autoreceptor, establish human translation, or provide experimental evidence about AVX-1.
- Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission — Hein L, Altman JD, Kobilka BK, Nature, 1999.
- Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice — Altman JD et al., Molecular Pharmacology, 1999.
Locus coeruleus autoregulation may not be homogeneous
Projection-defined mouse locus coeruleus neurons have shown differences in somatodendritic α2-autoreceptor function.
Classification. Preclinical evidence.
Relevance to Aeviant. The finding cautions against treating one receptor mechanism as physiologically identical across every circuit or tissue context.
Limitations. The work used adult male mouse slices and small projection-defined samples; it is not a clean demonstration of α2A alone and does not establish human relevance.
- Axonal projection-specific differences in somatodendritic α2 autoreceptor function in locus coeruleus neurons — Wagner-Altendorf TA, Fischer B, Roeper J, European Journal of Neuroscience, 2019.
α2A signalling has measurable time-dependent kinetics
Cell-based FRET measurements described fast, nonequilibrium activation of α2A and downstream Gi by norepinephrine.
Classification. Preclinical evidence.
Relevance to Aeviant. The work provides a mechanistic example of why temporal context can matter when receptor pharmacology is evaluated.
Limitations. The study used engineered sensors in living cells rather than native neurons or in vivo physiology and contains no evidence about an α2A PAM or AVX-1.
- Nonequilibrium activation of a G-protein-coupled receptor — Ambrosio M, Lohse MJ, Molecular Pharmacology, 2012.
Positive allosteric modulation is defined relative to a specified orthosteric ligand and context
IUPHAR nomenclature distinguishes orthosteric agonism, allosteric agonism, and positive allosteric modulation, and emphasizes probe, pathway, tissue, and assay dependence.
Classification. Established biology.
Relevance to Aeviant. This framework supports the terminology used to describe the AVX-1 program objective.
Limitations. Consensus nomenclature does not validate AVX-1. Ligand dependence, intrinsic activity, subtype selectivity, and signalling behaviour require experimental measurement.
- International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands — Christopoulos A et al., Pharmacological Reviews, 2014.
- IUPHAR/BPS Guide to PHARMACOLOGY: α2A-adrenoceptor
Further reading: Tonic and phasic signalling, the evidence library, and AVX-1.